Qurient Co., Ltd.

▎药明康德内容团队编辑 本期看点 1. 用于治疗溃疡性结肠炎（UC）的口服抗体疗法达到1b期临床试验的主要目标，并在多个临床终点方面展现良好的活性。 2. 中枢神经系统（CNS）渗透性TYK2抑制剂A-005取得积极的1期临床试验结果，具有良好的耐受性，并能穿越血脑屏障。 3. 用于治疗慢性乙型肝炎病毒（HBV）感染的下一代衣壳组装调节剂（CAM）ABI-4334在1b期临床试验中展现强力的抗病毒活性，28天使患者血浆HBV DNA平均降低了2.9 log IU/mL。 药明康德内容团队整理 SOR102：公布1b期临床试验数据 Sorriso Pharmaceuticals公司公布了其针对溃疡性结肠炎患者的口服TNFα和IL-23双效生物制品SOR102的积极1b期临床试验结果。SOR102通过在发炎组织内部提供局部组合疗法，同时尽量减少全身暴露，有望通过同时阻断炎症性肠病的不同机制来提高疗效。 此次公布的结果显示，该研究达到了主要目标，显示出良好的安全性和耐受性。此外，关键的探索性疗效终点结果显示，SOR102在多个临床终点方面具有良好的活性。具体表现为，在完成研究的患者中，高剂量SOR102组患者在多个临床终点上与安慰剂组患者相比达到了统计学上的显著差异，包括Mayo评分临床缓解、改良Mayo评分临床缓解、症状缓解，以及Mayo评分、改良Mayo评分和UC-100评分与基线相比的平均下降值。新闻稿指出，该研究结果首次成功证明了口服抗体能够产生临床疗效。 A-005：公布1期临床试验数据 Alumis公司公布了其强效、选择性、CNS渗透性TYK2抑制剂A-005的1期临床试验的积极数据。新闻稿指出，A-005是首个公开的TYK2变构抑制剂。该候选疗法旨在实现最大的TYK2抑制效果，并能够穿越血脑屏障，在CNS内部和外周进行局部治疗，支持其在多个TYK2介导适应症中的潜力。该候选疗法正在开发用于治疗神经炎症和神经退行性疾病，如多发性硬化（MS）和帕金森病。 此次公布的结果显示，A-005具有良好的耐受性，并能穿越血脑屏障。此外，A-005在CNS和外周实现了最大的TYK2抑制，并具有良好的药代动力学特征。基于这些数据，该公司预计在2025年下半年开始，在MS患者中进行2期临床试验。 ABI-4334：公布1b期临床试验数据 Assembly Biosciences公司公布了其在研下一代衣壳组装调节剂ABI-4334用于治疗慢性HBV感染患者的1b期临床试验数据。此次公布的结果显示，在首个150 mg剂量组中，ABI-4334显示出很强的抗病毒活性，在28天的治疗中，血浆HBV DNA平均降低了2.9 log IU/mL。此外，ABI-4334耐受性良好，具有良好的安全性，半衰期支持每日一次口服给药。 VYN202：公布1a期临床试验的新数据 VYNE Therapeutics公司公布了其口服小分子BET抑制剂VYN202的积极1a期临床试验结果。新闻稿指出，相对于BD1，VYN202对BD2具有潜在“class-leading”的选择性和效力。此次公布的结果显示，VYN202有潜力成为一种新型的、每日一次的口服药物，用于治疗广泛的免疫介导疾病。与1a期单剂量递增结果一致，VYN202展现了良好的安全性和耐受性特征，没有出现与早期选择性较低的BET抑制剂相关的药物相关不良事件。此外，VYN202在体外刺激试验中展现了强大的药理活性，包括靶点结合和显著抑制与几种免疫介导疾病相关的炎症生物标志物的证据。 MF-300：IND申请获得FDA许可 Epirium Bio公司宣布，美国FDA已批准其潜在“first-in-class”的口服15-羟基前列腺素脱氢酶（15-PGDH）抑制剂MF-300的IND申请，用于治疗肌肉减少症或年龄引起的肌无力。15-PGDH是一种能将前列腺素E2（PGE2）转化为非活性代谢物的酶。MF-300旨在可逆地结合到15-PGDH的PGE2结合位点上，阻止该酶转化PGE2。在生化试验中，MF-300能够抑制15-PGDH的活性。在临床前的细胞和动物研究中，MF-300可稳定和增加PGE2的水平。2024年12月，该公司已开始为MF-300的1期剂量递增研究招募患者。 Adrixetinib：IND申请获得FDA许可 Qurient宣布，美国FDA已批准其免疫肿瘤药物adrixetinib的IND申请，可开展针对慢性移植物抗宿主病（cGVHD）的1b期临床试验。Adrixetinib是一种针对Axl、Mer和CSF1R的选择性三重激酶抑制剂。这种药物能增强机体的免疫防御能力，提高癌细胞对治疗的敏感性。新闻稿指出，adrixetinib能够通过抑制CSF1R治疗cGVHD，并通过抑制Axl/Mer治疗白血病，这种双重作用机制有望为同时治疗这两种疾病提供潜在的益处。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放 参考资料（可上下滑动查看） [1] Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B. Retrieved December 26, 2024, from https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-interim-phase-1b-results-clinical [2] Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005. Retrieved December 19, 2024, from https://www.globenewswire.com/news-release/2024/12/19/2999795/0/en/Alumis-Announces-Positive-Phase-1-Data-for-CNS-Penetrant-TYK2-Inhibitor-A-005.html [3] Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis. Retrieved December 19, 2024, from https://www.businesswire.com/news/home/20241219004563/en/Sorriso-Pharmaceuticals-Announces-Positive-Phase-1b-Clinical-Trial-Results-for-SOR102-in-Ulcerative-Colitis [4] VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor. Retrieved December 23, 2024, from https://www.globenewswire.com/news-release/2024/12/23/3001168/0/en/VYNE-Therapeutics-Reports-Positive-Top-line-Phase-1a-MAD-Data-for-VYN202-its-Novel-BD2-Selective-BET-Inhibitor.html [5] Epirium Bio Announces FDA Clearance of Investigational New Drug Application for MF-300 and Appointment of Alex Casdin as New Chief Executive Officer and Russell Cox as Executive Chairman. Retrieved December 23, 2024, from https://epirium.com/wp-content/uploads/2024/12/Epirium-Bio-Announces-FDA-Clearance-of-IND-Application-for-MF-300-and-Appointment-of-Alex-Casdin-as-New-CEO-and-Russell-Cox-as-Executive-Chairman.pdf [6] Qurient's Adrixetinib receives FDA IND approval for chronic graft-versus-host disease trial. Retrieved January 3, 2025, from https://www.koreabiomed.com/news/articleView.html?idxno=26208 [7] Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma. Retrieved December 19, 2024, from https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-provides-clinical-update-mt-601-patients [8] Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma. Retrieved December 19, 2024, from https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-announces-first-patient-dosed-phase-1-clinical-trial [9] Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101. Retrieved December 19, 2024, from https://www.globenewswire.com/news-release/2024/12/19/3000160/0/en/Vittoria-Biotherapeutics-Announces-Dosing-of-First-Patient-in-Phase-1-Clinical-Trial-of-VIPER-101.html [10] Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1. Retrieved December 19, 2024, from https://www.globenewswire.com/news-release/2024/12/19/2999724/0/en/Arbor-Biotechnologies-Announces-FDA-Acceptance-of-IND-Application-for-ABO-101-for-the-Treatment-of-Primary-Hyperoxaluria-Type-1.html [11] RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial. Retrieved January 3, 2025, from https://www.globenewswire.com/news-release/2024/12/20/3000558/0/en/RAD-202-Receives-Approval-to-Start-Phase-1-Therapeutic-Trial.html [12] Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody. Retrieved January 3, 2025, from https://ir.orukatx.com/news-releases/news-release-details/oruka-therapeutics-announces-first-participants-dosed-phase-1 [13] Holoclara Initiates Phase 1 Clinical Trial Evaluating Worm-Derived Therapeutic HC002 in Healthy Adults. Retrieved January 3, 2025, from https://www.businesswire.com/news/home/20241218604766/en/Holoclara-Initiates-Phase-1-Clinical-Trial-Evaluating-Worm-Derived-Therapeutic-HC002-in-Healthy-Adults/ [14] SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections. Retrieved January 3, 2025, from https://ir.scynexis.com/news-events/press-releases/detail/342/scynexis-initiates-dosing-in-phase-1-trial-of-scy-247-a [15] Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME. Retrieved January 3, 2025, from https://www.immunocore.com/investors/news/press-releases/detail/105/immunocore-announces-first-patient-dosed-in-the-phase-1-trial-of-imc-p115c-a-half-life-extended-hle-immtac-candidate-in-patients-with-tumors-that-express-prame [16] Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease. Retrieved January 3, 2025, from https://gaintherapeutics.com/newsroom/press-releases/press-releases-2024/gain-therapeutics-initiates-phase-1b-clinical-trial-of-lead-candidate-gt-02287-in-people-with-gba1-and-idiopathic-parkinsons-disease/ [17] Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity. Retrieved January 3, 2025, from https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-initiates-phase-1-2a-study-of-aro-inhbe-for-the-treatment-of-obesity/ 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新

SEONGNAM-SI, South Korea--(BUSINESS WIRE)-- Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to evaluate Qurient’s proprietary CDK7 inhibitor, Q901, in combination with an antibody drug conjugate (ADC) targeting tumor-associated calcium signal transducer 2 (TROP2) with topoisomerase 1 inhibitor payload for the treatment of small cell lung cancer (SCLC) and other relapsed solid tumors. Q901 is a highly selective CDK7 inhibitor under Phase 1/2 clinical development in the United States and South Korea. Qurient demonstrated Q901’s main mechanism of action as transcriptional inhibition of essential genes for tumor progression, including genes involved in DNA damage repair response, which led to strong synergy with a topoisomerase 1 inhibitor (Ref: DOI: 10.1158/1538-7445.AM2024-5712). These results are consistent with prior findings from Dr. Anish Thomas’ team at NCI, which revealed a synergistic mechanism between CDK7 inhibition and topoisomerase 1 inhibition (Ref: DOI: 10.1158/1535-7163.MCT-21-0891). Under this CRADA, NCI and Qurient will collaborate on an NCI-sponsored Phase 1/2 clinical study of Q901 in combination with the TROP2-ADC in SCLC and other relapsed solid tumors, starting from combination dose escalation and evaluating the safety, efficacy, and potential synergy of this novel combination. This collaboration is focused on development and evaluation of this innovative therapy for patients with extensive stage SCLC. "The collaboration between the NCI and Qurient is based on the science discovered through independent research conducted by each institution," said Kiyean Nam, Ph.D., CEO of Qurient. "We hope the new combination therapy will help patients with small cell lung cancer, where current therapeutic options are limited." About Q901 Q901 is a highly selective covalently binding small molecule CDK7 inhibitor under Phase 1/2 clinical development. Q901 demonstrated strong tumor growth inhibition in multiple cancer models including HR+ breast cancer, pancreatic cancer, prostate cancer, ovarian cancer, and small cell lung cancer as a single agent, as well as in combination with other therapies. Q901 in combination with fulvestrant is in a clinical trial for HR+ breast cancer patients who are refractory to CDK4/6 inhibitor and estrogen therapy combination. About Qurient Qurient is a clinical-stage biopharmaceutical company based in South Korea and is listed on the Korea Exchange (KRX 115180). Qurient focuses on the development of novel therapeutics from discovery to human proof-of-concept stages through virtual R&D project management platform. For more information, please visit .

Telacebec will be developed to treat tuberculosis and few non-tuberculosis mycobacteria infections. Credit: Department of Pathology, Calicut Medical college / Wikimedia. South Korean biotechnology company Qurient has entered a licence agreement with TB Alliance for the development and commercialisation of telacebec (Q203). Under the deal, TB Alliance will have the exclusive global license to develop and market telacebec except in Russia, South Korea, and the Commonwealth of Independent States (CIS) countries. The first-in-class orally available investigational drug, Telacebec blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex. It will be developed to treat tuberculosis (TB) and other non-tuberculosis mycobacteria (NTM) infections. In preclinical and clinical studies, the drug showed potent efficacy against drug-sensitive and drug-resistant TB. It was successfully evaluated in Phase IIa early bactericidal activity (EBA) study for the treatment of TB. In March 2020, the findings from the trial were published in The New England Journal of Medicine . Qurient CEO Kiyean Nam said: “As telacebec’s unique mechanism of action of blocking energy metabolism of the Mycobacterium can address all types of TB, including drug-resistant TB, we expect telacebec to potentially become an essential component of drug combination regimens for the treatment of TB. “We believe telacebec will greatly contribute to the global efforts to combating the TB pandemic, which remains a serious public health challenge worldwide. “Our partnership with the TB Alliance will accelerate the widespread availability of telacebec and bring it to those in need.” The US Food and Drug Administration (FDA) has granted Fast Track Designation and Orphan Drug Designation to telacebec. The drug was also found to be effective against buruli ulcer (Mycobacterium ulcerans), a chronic, necrotising disease that affects the skin and sometimes bone. TB Alliance president and CEO Mel Spigelman said: “New drugs like telacebec are urgently needed in the fight against TB as well as certain NTM infections – compounds with potentially impactful novel mechanisms of action can have a significant benefit in combating the TB pandemic. “We look forward to advancing this new compound as part of combination regimens that could yield a short, simple, safe, and highly effective cure for all forms of TB.”